Juxin Medical Technology (Zhongshan) Co., Ltd. has recently declared the successful closure of its Series C funding round, amassing close to 200 million yuan. This round of financing was spearheaded by the Zhongshan Biomedicine Angel Fund, with contributions from several institutions, and saw continued support from an existing shareholder, Zhuhai Hi-Tech Golden Investment. The newly acquired funds will be predominantly allocated towards the research and development of cutting-edge brain-computer interface technologies.

Established in 2020 and headquartered in Shenzhen, Juxin Medical Technology stands out as an innovative high-tech medical device enterprise, focusing on the creation of cardiovascular and cerebrovascular intervention products. The company operates a state-of-the-art laboratory and is led by a core team boasting a wealth of experience.

In its nascent stages, Juxin Medical Technology has already forged a comprehensive product matrix tailored for the interventional treatment of cerebrovascular diseases. It has also finalized the development of core components and underlying technologies essential for brain-computer interfaces. The company has successfully crafted a "Heart Repair and Brain Protection" medical device solution, which has undergone rigorous clinical trial validation.

Looking to the future, Juxin Medical Technology envisions constructing an open and pioneering brain medicine technology platform. CEO Huang Hui emphasized that the company has consistently been guided by clinical needs, and the successful commercialization of its stroke treatment products serves as a testament to the team's prowess. By 2025, the company aims to have established a nationwide commercial distribution network and is actively venturing into international markets, leveraging its existing resources to further bolster the research and development of brain-computer interface technologies.